Yan Leyfman, Medical Oncologist, Co-Founder and Executive Director of MedNews Week, shared a post on LinkedIn:
“Real-world experience with CD20-directed bispecific antibodies (BsAbs) in R/R DLBCL.
Epcoritamab and glofitamab are now approved in the U.S. for relapsed/refractory diffuse large B-cell lymphoma (DLBCL), but real-world outcomes outside of trials have been limited—until now.
Across 245 patients treated at 21 U.S. centers (Jan 2023–Oct 2024):
- ORR: 51% with epcoritamab (23% CR); 53% with glofitamab (30% CR)
- Median PFS: 2.6 months; Median OS: 7.8 months
- CD20 loss occurred in 88% (15/17) of patients with paired biopsies
- Patients ineligible for registrational trials and those with undetectable baseline CD20 had inferior outcomes
Despite shorter PFS/OS than pivotal trials, BsAbs remain active and meaningful options for heavily pretreated R/R DLBCL. These findings highlight the importance of antigen persistence and the need for strategies to prevent or overcome CD20 loss.”
Title: Real-world outcomes of patients with aggressive B-cell lymphoma treated with epcoritamab or glofitamab
Authors: Taylor R. Brooks, Emily C. Zabor, Yohanna B. Bedelu, Xi Yang, Yasmin H. Karimi, Adrienne N. Nedved, Yucai Wang, Nikita Dave, Daniel J. Landsburg, Kelsey Baron, Boyu Hu, Daniel C. Trotier, Priyanka A. Pophali, Jordan Miller, Natalie Grover, Catherine Reinert, Ajay Major, Tenley Schwarz, Krish Patel, Kiarash Salafian, Emily Ayers, Suchitra Sundaram, Joshua D. Brody, Marshall McKenna, Yun Kyoung Ryu Tiger, Megan Sears-Smith, Nilanjan Ghosh, Chelsea Peterson, Cyrus Khan, Sean P. Bliven, Mayur Narkhede, Alyssa Gibson, Justin Kline, Javier Munoz, Rodolfo Garza-Morales, Carrie I. Ho, Stephen D. Smith, Alex Niu, Francisco Hernandez-Ilizaliturri, Fadzai Chinyengetere, Sandeep Dave, Nayef Abdel-Razeq, Muhamad Alhaj Moustafa, Paolo F. Caimi, Brian T. Hill
More posts featuring Yan Leyfman on OncoDaily.